Search

Displaying results 3471 - 3480 of 6835 in total
  1. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

  2. Drug

    Zopiclone

    go.drugbank.com/drugs/DB01198
    ApprovedInvestigational

    In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

  3. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    when compared to [crizotinib]. … [A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously

  4. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to

  5. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. … The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug.

  6. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

  7. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100] … It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019.

  8. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.

  9. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen MixProducts: GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT 100 TABLET, GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT TABLET, 30 ADET
  10. Drug

    Diethylstilbestrol

    go.drugbank.com/drugs/DB00255
    ApprovedWithdrawn

    According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen.